NICE recommendations

top of page

NICE Opens Access to New Immunotherapy in Cervical Cancer and First Disease‑Modifying Drug in Early Type 1 Diabetes

Badari Andukuri

Jun 28

NICE recommends Spinraza and Evrysdi for routine use; Imfinzi for aggressive stomach cancer

NICE recommends Spinraza and Evrysdi for routine use; Imfinzi for aggressive stomach cancer

NICE recommends Spinraza and Evrysdi for routine use; Imfinzi for aggressive stomach cancer

ipharmaservices

May 14

NICE recommends Duvyzat for Duchenne muscular dystrophy

NICE recommends Duvyzat for Duchenne muscular dystrophy

NICE recommends Duvyzat for Duchenne muscular dystrophy

Badari Andukuri

May 9

NICE Recommends First Vitiligo Treatment for Use in the NHS

Badari Andukuri

Mar 3

NHS England lowers FIT threshold to catch more bowel cancers early

ipharmaservices

Jan 27

NICE greenlights Dupixent as add-on therapy for uncontrolled COPD with raised eosinophils in England, marking first targeted biologic for this indication | iPharmaCenter

ipharmaservices

Jan 27

NICE’s New £35k/QALY Era: Ripple Effects for Australia’s PBS and Other HTA Markets | NICE Cost Effectiveness Threshold | iPharmaCenter

NICE’s New £35k/QALY Era: Ripple Effects for Australia’s PBS and Other HTA Markets | NICE Cost Effectiveness Threshold | iPharmaCenter

NICE’s New £35k/QALY Era: Ripple Effects for Australia’s PBS and Other HTA Markets | NICE Cost Effectiveness Threshold | iPharmaCenter

Badari Andukuri

Dec 2, 2025

NICE increased cost effectiveness threshold from £20,000-£30,000/QALY to £25,000-£35,000/QALY

Badari Andukuri

Dec 1, 2025

NICE Approves Autolus’ Obe-cel CAR-T Therapy for Adults with Rare Blood Cancer | iPharmaCenter

ipharmaservices

Nov 25, 2025

NICE Recommends Vertex's £1.6 Million One-Time Gene Therapy Casgevy for Beta-Thalassaemia | iPharmaCenter

NICE Recommends Vertex's £1.6 Million One-Time Gene Therapy Casgevy for Beta-Thalassaemia | iPharmaCenter

NICE Recommends Vertex's £1.6 Million One-Time Gene Therapy Casgevy for Beta-Thalassaemia | iPharmaCenter

ipharmaservices

Aug 14, 2024

NICE Endorses Almirall's Ebglyss for Treating Moderate to Severe Atopic Dermatitis | iPharmaCenter

ipharmaservices

Jul 20, 2024

NICE Recommends Relugolix for Advanced Prostate Cancer Treatment

ipharmaservices

Jul 20, 2024

Hemgenix Receives Managed Access Recommendation for Treating Severe Haemophilia B in Adults | iPharmaCenter

ipharmaservices

Jul 14, 2024

NICE said NO to Keytruda plus trastuzumab for HER2-positive gastric cancer | 2024 | iPharmaCenter

NICE said NO to Keytruda plus trastuzumab for HER2-positive gastric cancer | 2024 | iPharmaCenter

NICE said NO to Keytruda plus trastuzumab for HER2-positive gastric cancer | 2024 | iPharmaCenter

ipharmaservices

Jun 13, 2024

Servier Laboratories' Tibsovo Combined with Azacitidine Recommended by NICE for Adult Patients with Newly Diagnosed AML with IDH1 Mutation | iPharmaCenter

ipharmaservices

Jun 7, 2024

NICE recommended AbbVie's Aquipta for migraine | United Kingdom |Healthcare News | iPharmaCenter

NICE recommended AbbVie's Aquipta for migraine | United Kingdom |Healthcare News | iPharmaCenter

NICE recommended AbbVie's Aquipta for migraine | United Kingdom |Healthcare News | iPharmaCenter

ipharmaservices

May 15, 2024

NICE recommended the use of AI-derived solutions to detect stroke | iPharmaCenter

NICE recommended the use of AI-derived solutions to detect stroke | iPharmaCenter

NICE recommended the use of AI-derived solutions to detect stroke | iPharmaCenter

ipharmaservices

May 3, 2024

NICE Assessment Outcomes | Untied Kingdom | Drug News | Updates | 2024 | iPharmaCenter

NICE Assessment Outcomes | Untied Kingdom | Drug News | Updates | 2024 | iPharmaCenter

NICE Assessment Outcomes | Untied Kingdom | Drug News | Updates | 2024 | iPharmaCenter

ipharmaservices

May 1, 2024

NICE ASSESSMENT OUTCOMES | 2023 | (2/N) | UK HEALTHCARE NEWS | IPHARMACENTER

NICE ASSESSMENT OUTCOMES | 2023 | (2/N) | UK HEALTHCARE NEWS | IPHARMACENTER

NICE ASSESSMENT OUTCOMES | 2023 | (2/N) | UK HEALTHCARE NEWS | IPHARMACENTER

ipharmaservices

Sep 8, 2023

NICE ASSESSMENT OUTCOMES | 2023 (1/N) United Kingdom | Healthcare | Pharma | News | iPharmaCenter

NICE ASSESSMENT OUTCOMES | 2023 (1/N) United Kingdom | Healthcare | Pharma | News | iPharmaCenter

NICE ASSESSMENT OUTCOMES | 2023 (1/N) United Kingdom | Healthcare | Pharma | News | iPharmaCenter

ipharmaservices

Apr 6, 2023

bottom of page